Quick Answer
Chicory Root Fiber Blood Glucose Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo.
Key Takeaways
- 01Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo. [Kerezoudi EN (2026)]
- 02In an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21. [Kerezoudi EN (2026)]
- 03Conclusion: Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient. [Kerezoudi EN (2026)]
- 04Background: Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis. [Kerezoudi EN (2026)]
The current Migaku evidence database contains 2 reusable source documents for Chicory Root Fiber Blood Glucose Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts.
- Clinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo. [Kerezoudi EN (2026); evidence level 4]
- In an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21. [Kerezoudi EN (2026); evidence level 4]
- Conclusion: Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient. [Kerezoudi EN (2026); evidence level 4]
- Background: Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis. [Kerezoudi EN (2026); evidence level 4]
- Interestingly, we previously found that short-term (3 weeks), daily intake of 30 g/day of dried chicory root fibers in individuals at risk of T2D rapidly modulated the gut microbiota by increasing relative levels ofspp. [Omary Lina (2025); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources